New American Thyroid Association and American Association of Clinical Endocrinologists Guidelines for Thyrotoxicosis and Other Forms of Hyperthyroidism: Significant Progress for the Clinician and a Guide to Future Research
Restricted accessEditorialFirst published online June, 2011
New American Thyroid Association and American Association of Clinical Endocrinologists Guidelines for Thyrotoxicosis and Other Forms of Hyperthyroidism: Significant Progress for the Clinician and a Guide to Future Research
ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis. BahnRS, BurchHB, CooperDS, GarberJR, GreenleeMC, KleinI, LaurbergP, McDougallR, MontoriVM, RivkeesSA, RossDS, SosaJA, StanMN. 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, 21:593–646.
2.
SingerPA, CooperDS, LevyEG, LadensonPW, BravermanLE, DanielsG, GreenspanFS, McDougallIR, NikolaiTF. 1995. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA, 273:808–812.
3.
BaskinHJ, CobinRH, DuickDS, GharibH, GuttlerRB, KaplanMM, SegalRL. 2002. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 8:457–469.
4.
American Thyroid Association. 2000. ATA supports FDA warning on Triax, February 26, 2000. www.thyroid.org/professionals/publications/statements/00_02_26_triax.html. 2011 April 25.
5.
CooperDS. 2005. Antithyroid drugs. N Engl J Med, 352:905–917.
6.
EzerA, CaliskanK, ParlakgumusA, BelliS, KozanogluI, YildirimS. 2009. Preoperative therapeutic plasma exchange in patients with thyrotoxicosis. J Clin Apher, 24:111–114.
7.
GuvencB, UnsalC, GurkanE, DincerS. 2004. Plasmapheresis in the treatment of hyperthyroidism associated with agranulocytosis: a case report. J Clin Apher, 19:148–150.
8.
VyasAA, VyasP, FilliponNL, VijayakrishnanR, TrivediN. 2010. Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis. Endocr Pract, 16:673–676.
9.
GreenleeC, BurmeisterLA, ButlerRS, EdinboroCH, MorrisonSM, MilasM. 2011. Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners. Thyroid, 21:151–160.
10.
The American Thyroid Association Taskforce on Radioiodine Safety. SissonJC, FreitasJ, McDougallIR, DauerLT, HurleyJR, BrierleyJD, EdinboroCH, RosenthalD, ThomasMJ, WexlerJA, AsamoahE, AvramAM, MilasM, GreenleeC. 2011. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid, 21:335–346.
11.
PrombergerR, OttJ, KoberF, KarikM, FreissmuthM, HermannM. 2011. Normal parathyroid hormone levels do not exclude permanent hypoparathyroidism after thyroidectomy. Thyroid, 21:145–150.
12.
SurksMI, OrtizE, DanielsGH, SawinCT, ColNF, CobinRH, FranklynJA, HershmanJM, BurmanKD, DenkeMA, GormanC, CooperRS, WeissmanNJ. 2004. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA, 291:228–238.
13.
GharibH, TuttleRM, BaskinHJ, FishLH, SingerPA, McDermottMT. 2005. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society. Thyroid, 15:24–28.
